ArticleIndian journal of ophthalmology2026
Cholesterol metabolism dysregulation in eyelid sebaceous gland carcinoma and its clinical significance.
Article in Indian journal of ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeEyelid sebaceous gland carcinoma (SGC) is a rare and aggressive malignancy of the eyelids. Dysregulated cholesterol metabolism has been found to be involved in pathogenesis of various cancers including glioblastoma, breast, prostate, and pancreatic cancer. The role of cholesterol metabolism in SGC and its molecular characterization remains unexplored. This study evaluates the clinical significance of the expression of a key enzyme involved in cholesterol metabolism, acyl-CoA cholesterol acyltransferase 1 (ACAT1) in eyelid SGC.
methodsA cohort of 50 eyelid SGC cases diagnosed over a period of 12 years were selected. Cholesterol quantification, immunohistochemistry (IHC), and real-time PCR to determine the protein and mRNA expression of ACAT were performed.
resultsIncreased concentration of total cholesterol, free cholesterol, and cholesteryl esters was observed in SGC tumor tissues. Overexpression of ACAT1 at protein and mRNA levels was observed in 66% of the eyelid SGC patients. Significant association of high ACAT1 mRNA expression was observed in patients with lymph node metastasis ( P = 0.03) and advanced (III/IV) tumor stage ( P = 0.02). SGC patients with a high ACAT immunoexpression also had reduced disease-free survival.
conclusionOverexpression of ACAT1 is a frequent event in the pathogenesis of eyelid SGC and is associated with high risk clinicopathological features. It could serve as a reliable poor prognostic biomarker.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.